Camurus AB

Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence; episil oral liquid, a medical device for the treatment of inflammatory and painful conditions in the oral cavity; and Brixadi to treat opioid use disorder Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. Show More...

  • Website https://www.camurus.com
  • Sector Healthcare
  • Industry Biotechnology
  • Last Quote 511.50 SEK
  • Last Updated 30-05-2025
  • External Links Yahoo Finance Morningstar Ratios
  •   2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM
    Earnings Per Share SEK 0.33 2.43 1.18 -5.51 -1.99 -4.68 -5.77 -6.23 -5.8
    Dividends SEK
    Payout Ratio % *
    Shares Mil 41.0 41.0 41.0 41.0 41.0 42.0 42.0 49.0 51.0
    Book Value Per Share * SEK 2.53 14.53 10.73 8.1 8.09 11.05
    Free Cash Flow Per Share * SEK 2.4 -4.0 -3.87 -5.99 -8.09
    Return on Assets % 18.34 117.4 30.28 -31.16 -11.12 -34.16 -55.83 -51.0 -39.59
    Financial Leverage (Average) 1.43 2.23 1.68 1.27 1.13 1.24 1.45 1.22 1.28
    Return on Equity % 51.46 219.89 55.73 -41.76 -13.44 -40.15 -73.64 -65.58 -50.15
    Return on Invested Capital % 54.06 219.98 55.53 -41.73 -13.33 -40.17 -73.68 -61.5 -47.66
    Interest Coverage 20.8 368.9 -102.15 -227.12 -224.34
    Current Ratio 3.05 1.53 2.35 4.26 7.29 3.68 1.48 3.74 2.78
    Quick Ratio 2.83 1.44 2.31 4.23 7.07 3.58 1.31 3.41 2.45
    Debt/Equity 0.04 0.04